Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done

An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

Twitter Is Elon Musk’s Biggest Test—and Tesla’s Biggest Challenge. How They’ll Make It Work.

Elon Musk officially owns Twitter—and now the hand-wringing about his ability to oversee the rest of his empire has begun again. Of all the concerns around Tesla however, Musk’s ability to manage his ...

Tesla Stock Today: Elon Musk’s Twins, EV Charging and What Else to Know

Text size It was revealed that Tesla CEO Elon Musk had twins last year with one of his top executives. Getty Images Shares of electric vehicle maker Tesla rose 1% in premarket trading Thursday. Here’s...

These ‘zombie’ companies could feel the cash burn, warns New Constructs

Carvana Co., Freshpet Inc. and Peloton Interactive Inc. could feel the cash burn as the Fed raises interest rates, according to independent equity research firm New Constructs. The research firm, whic...

The Days of Big Pharma Are Over. Big Biotech Is on Its Way.

W hen GlaxoSmithKline spins off its enormous division selling drugstore staples like Advil and Tums next month, it will represent more than just the latest shuffling of assets among corporate giants. ...

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GSK

Text size The deal comes ahead of GlaxoSmithKline’s planned spinoff of its consumer health division in July. AFP via Getty Images GlaxoSmithKline has agreed to buy U.S. rare cancer therapy compa...

Sierra Oncology Stock Soars After $1.9 Billion Takeover by GlaxoSmithKline

Text size AFP via Getty Images GlaxoSmithKline has agreed to buy U.S. rare cancer therapy company Sierra Oncology for $1.9 billion in cash, as it looks to boost its portfolio of new specialty medicine...

Cannabis company that DEA is allowing to grow for research purposes to list shares on Nasdaq

Bright Green Corp., a Fort Lauderdale, Fla.-based company with conditional approval from the U.S. Drug Enforcement Administration (DEA) to produce federally legal cannabis, on Tuesday filed plans to d...

Freed Huawei Finance Chief Meng Wanzhou Returns to Company Spotlight

HONG KONG—Months after returning home to a hero’s welcome in China, Huawei Technologies Co. finance chief Meng Wanzhou was back in the spotlight Monday: This time, she was in more familiar surrounding...

Biotech Stocks Are Due to Bounce Back. This One Stands Out.

Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...